Telitacicept
As of the edition of 20 October 2026, Telitacicept is a protein: in active development; acts on TNFSF13B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Protein
- Registered trials
- 49, 5 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive; Nervous system; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFSF13B | Tumor necrosis factor ligand superfamily member 13B | Q9Y275 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 0 | 6 | 0 |
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 15 | 1 | 10 | 3 |
| Phase 3 | 15 | 2 | 10 | 2 |
| Phase 4 | 8 | 0 | 5 | 0 |
| All trials | 49 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| RemeGen | Lead sponsor of trials | 2021 to now |
| Vor Biopharma | Lead sponsor of trials | 2022 to now |
| ADARx Pharmaceuticals | Lead sponsor of trials | 2026 to now |
| Innovent Biologics | Lead sponsor of trials | 2026 to now |